Supernus Pharmaceuticals (NASDAQ:SUPN) Hits New 1-Year Low – Time to Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $42.39 and last traded at $42.42, with a volume of 129584 shares traded. The stock had previously closed at $43.53.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on SUPN. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald upped their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, July 9th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen cut shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $62.83.

Supernus Pharmaceuticals Stock Down 2.5%

The stock has a market cap of $2.47 billion, a P/E ratio of -22.10, a P/E/G ratio of 0.80 and a beta of 0.56. The firm has a 50 day moving average price of $46.62 and a 200 day moving average price of $48.34.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The company had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. During the same quarter last year, the firm posted $0.40 earnings per share. The company’s revenue was up 32.4% compared to the same quarter last year. Equities analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 earnings per share for the current fiscal year.

Institutional Trading of Supernus Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Public Employees Retirement System of Ohio bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth $25,000. Rockefeller Capital Management L.P. lifted its position in shares of Supernus Pharmaceuticals by 354.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 660 shares in the last quarter. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals in the second quarter valued at about $51,000. Hantz Financial Services Inc. boosted its stake in shares of Supernus Pharmaceuticals by 73.3% in the fourth quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 458 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Supernus Pharmaceuticals in the second quarter worth about $55,000.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained?release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended?release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended?release capsules), approved for the treatment of attention?deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.